Genmab Dividends and Buybacks
Dividend criteria checks 0/6
Genmab does not have a record of paying a dividend.
Key information
n/a
Dividend yield
4.1%
Buyback Yield
Total Shareholder Yield | 4.1% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Genmab Is Too Attractive To Ignore
Dec 08Genmab: Looking To Manage My Position Around Q3 Earnings
Nov 06Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
Aug 23Genmab: A Complicated Tale
May 01Genmab Acquires A Missing Piece For Its Pipeline
Apr 16Genmab: Recent Updates Support The Growth Narrative
Feb 21Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)
Jan 23Genmab: 3 Trends To Track For A Strong 2024 And Beyond
Jan 12Genmab reports Q3 worldwide sales of $2.05B for Darzalex
Oct 18Genmab improves FY 2022 guidance
Aug 08Genmab reports Q2 worldwide net sales of DARZALEX $1.99B
Jul 19Genmab: A Royalty Powerhouse With A Strong Pipeline
Jun 28Genmab: Looking For Growth At A Reasonable Price
Jun 10Genmab: A Biotech Company On The Rise
Mar 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if GMAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GMAB's dividend payments have been increasing.
Dividend Yield vs Market
Genmab Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (GMAB) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.5% |
Industry Average (Biotechs) | 2.5% |
Analyst forecast (GMAB) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate GMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate GMAB's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GMAB has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 12:42 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genmab A/S is covered by 45 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Andrew Carlsen | ABG Sundal Collier |
Armelle Moulin | AlphaValue |
Emily Field | Barclays |